APA (7th ed.) Citation

Zandberg, D. P., Algazi, A. P., Jimeno, A., Good, J. S., Fayette, J., Bouganim, N., . . . Jarkowski, A. (2019). Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. European Journal of Cancer, 107, 142. https://doi.org/10.1016/j.ejca.2018.11.015

Chicago Style (17th ed.) Citation

Zandberg, Dan P., et al. "Durvalumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from a Single-arm, Phase II Study in Patients with ≥25% Tumour Cell PD-L1 Expression Who Have Progressed on Platinum-based Chemotherapy." European Journal of Cancer 107 (2019): 142. https://doi.org/10.1016/j.ejca.2018.11.015.

MLA (9th ed.) Citation

Zandberg, Dan P., et al. "Durvalumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from a Single-arm, Phase II Study in Patients with ≥25% Tumour Cell PD-L1 Expression Who Have Progressed on Platinum-based Chemotherapy." European Journal of Cancer, vol. 107, 2019, p. 142, https://doi.org/10.1016/j.ejca.2018.11.015.